Literature DB >> 8797796

Characterization of mAb AP422, a novel phosphorylation-dependent monoclonal antibody against tau protein.

M Hasegawa1, R Jakes, R A Crowther, V M Lee, Y Ihara, M Goedert.   

Abstract

A monoclonal antibody (AP422) specific for phosphoserine 422 in microtubule-associated protein tau has been produced. It strongly labels paired helical filament (PHF) tau from Alzheimer's disease brain in a phosphorylation-dependent manner. By contrast, AP422 only labels a small fraction of fetal tau and a very small fraction of tau from adult brain. The amount of tau phosphorylated at Ser-422 in normal brain is minor relative to that phosphorylated at sites recognized by other phosphorylation-dependent anti-tau antibodies of known epitope. It follows that AP422 is the most specific anti-tau antibody available for detecting the neurofibrillary lesions of Alzheimer's disease. We also show that Ser-422 in tau is a good in vitro substrate for mitogen-activated protein kinase, but not for glycogen synthase kinase-3 or neuronal cdc2-like kinase.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8797796     DOI: 10.1016/0014-5793(96)00271-2

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  36 in total

1.  Stable expression in Chinese hamster ovary cells of mutated tau genes causing frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).

Authors:  N Matsumura; T Yamazaki; Y Ihara
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

2.  Progression of tau pathology in cholinergic Basal forebrain neurons in mild cognitive impairment and Alzheimer's disease.

Authors:  Laurel Vana; Nicholas M Kanaan; Isabella C Ugwu; Joanne Wuu; Elliott J Mufson; Lester I Binder
Journal:  Am J Pathol       Date:  2011-09-23       Impact factor: 4.307

3.  Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.

Authors:  Laetitia Troquier; Raphaelle Caillierez; Sylvie Burnouf; Francisco J Fernandez-Gomez; Marie-Eve Grosjean; Nadege Zommer; Nicolas Sergeant; Susanna Schraen-Maschke; David Blum; Luc Buee
Journal:  Curr Alzheimer Res       Date:  2012-05       Impact factor: 3.498

Review 4.  The tauopathies: toward an experimental animal model.

Authors:  M Goedert; M Hasegawa
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

Review 5.  Changes in the ageing brain in health and disease.

Authors:  B H Anderton
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1997-12-29       Impact factor: 6.237

6.  Pseudophosphorylation of tau at S422 enhances SDS-stable dimer formation and impairs both anterograde and retrograde fast axonal transport.

Authors:  Chelsea T Tiernan; Benjamin Combs; Kristine Cox; Gerardo Morfini; Scott T Brady; Scott E Counts; Nicholas M Kanaan
Journal:  Exp Neurol       Date:  2016-06-30       Impact factor: 5.330

7.  ASIP Outstanding Investigator Award Lecture. New approaches to the pathology and genetics of neurodegeneration.

Authors:  Mel B Feany
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

8.  Tau Oligomer Pathology in Nucleus Basalis Neurons During the Progression of Alzheimer Disease.

Authors:  Chelsea T Tiernan; Elliott J Mufson; Nicholas M Kanaan; Scott E Counts
Journal:  J Neuropathol Exp Neurol       Date:  2018-03-01       Impact factor: 3.685

9.  Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice.

Authors:  Stefan Kins; Pascal Kurosinski; Roger M Nitsch; Jürgen Götz
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

10.  Analysis of tau phosphorylation and truncation in a mouse model of human tauopathy.

Authors:  Patrice Delobel; Isabelle Lavenir; Graham Fraser; Esther Ingram; Max Holzer; Bernardino Ghetti; Maria Grazia Spillantini; R Anthony Crowther; Michel Goedert
Journal:  Am J Pathol       Date:  2007-12-13       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.